Scott D. Grimes - Dec 2, 2021 Form 4 Insider Report for Cardlytics, Inc. (CDLX)

Role
Director
Signature
/s/ Kirk Somers, Attorney-in-Fact
Stock symbol
CDLX
Transactions as of
Dec 2, 2021
Transactions value $
-$502,813
Form type
4
Date filed
12/6/2021, 04:08 PM
Previous filing
Nov 22, 2021
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDLX Common Stock Sale -$109K -1.7K -2.98% $64.34* 55.4K Dec 2, 2021 See Footnote F1, F2, F3
transaction CDLX Common Stock Sale -$19.6K -300 -0.54% $65.23* 55.1K Dec 2, 2021 See Footnote F1, F3, F4
transaction CDLX Common Stock Sale -$67.6K -1.1K -0.46% $61.43 240K Dec 3, 2021 Direct F5, F6
transaction CDLX Common Stock Sale -$237K -3.82K -1.59% $62.23* 236K Dec 3, 2021 Direct F5, F7
transaction CDLX Common Stock Sale -$43.1K -684 -0.29% $62.99* 235K Dec 3, 2021 Direct F5, F8
transaction CDLX Common Stock Sale -$19.2K -300 -0.13% $64.06* 235K Dec 3, 2021 Direct F5, F9
transaction CDLX Common Stock Sale -$6.52K -100 -0.04% $65.20* 235K Dec 3, 2021 Direct F5, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.
F2 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $63.82 to $64.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (6), (7), (8), (9), and (10) to this Form 4.
F3 The reportable securities are held by the GRAT.
F4 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $64.83 to $65.43, inclusive.
F5 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021.
F6 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.78, inclusive.
F7 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $61.85 to $62.84, inclusive.
F8 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $62.865 to $63.17, inclusive.
F9 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $64.05 to $64.08, inclusive.
F10 The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $65.19 to $65.35, inclusive.